Characterization of therapeutic monoclonal antibodies used in the context of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). IgA2 antibodies targeting CD38 were analyzed using LC-MS/MS. Mass analysis, peptide mapping and glycoprofiling were performed to confirm sequence integrity and post-translational modifications. The analysis supports preclinical evaluation of antibody-based immunotherapies and provides insights into glycosylation relevant for effector function.